[1]
|
Neuberger, J. (2000) Liver Transplantation. Journal of Hepatology, 32, 198-207.
https://doi.org/10.1016/S0168-8278(00)80426-2
|
[2]
|
Sudan, D.L., Venkataramani, A., Lynch, J., et al. (1999) Causes of Late Mortality in Survivors of Liver Transplantation. Transplantation, 67, S564. https://doi.org/10.1097/00007890-199905150-00110
|
[3]
|
Rabkin, J.M., de La Melena, V., Orloff, S.L., et al. (2001) Late Mortality after Orthotopic Liver Trans-Plantation. The American Journal of Surgery, 181, 475-479. https://doi.org/10.1016/S0002-9610(01)00595-5
|
[4]
|
Gelson, W., Hoare, M., Dawwas, M.F., et al. (2011) The Pattern of Late Mortality in Liver Trans-Plant Recipients in the United Kingdom. Transplantation, 91, 1240-1244. https://doi.org/10.1097/TP.0b013e31821841ba
|
[5]
|
Asfar, S., Metrakos, P., Fryer, J., et al. (1996) An Analysis of Late Deaths after Liver Transplantation. Transplantation, 61, 1377-1381. https://doi.org/10.1097/00007890-199605150-00016
|
[6]
|
Wallia, A., Parikh, N.D., Molitch, M.E., et al. (2010) Posttransplant Hyperglycemia Is Associated with Increased Risk of Liver Allograft Rejection. Transplantation, 89, 222-226. https://doi.org/10.1097/TP.0b013e3181c3c2ff
|
[7]
|
Gómez-Manero, N., Herrero, J.I., Quiroga, J., et al. (2001) Prognostic Model for Early Acute Rejection after Liver Transplantation. Liver Transplantation, 7, 246-254. https://doi.org/10.1053/jlts.2001.22460
|
[8]
|
Ziolkowski, J., Paczek, L., Niewczas, M., et al. (2003) Acute Liver Transplant Rejection: Incidence and the Role of High-Doses Steroids. Transplantation Proceedings, 35, 2289-2291. https://doi.org/10.1016/S0041-1345(03)00797-8
|
[9]
|
Naesens, M. and Sarwal, M.M. (2010) Monitoring Calcineu-rin Inhibitor Therapy: Localizing the Moving Target. Transplantation, 89, 1308-1309. https://doi.org/10.1097/TP.0b013e3181dc13fa
|
[10]
|
Post, D.J., Douglas, D.D. and Mulligan, D.C. (2005) Immu-nosuppression in Liver Transplant. Liver Transplantation, 11, 1307-1314. https://doi.org/10.1002/lt.20614
|
[11]
|
Gonwa, T.A., Mai, M.L., Melton, L.B., et al. (2001) End-Stage Renal Disease (ESRD) after Orthotopic Liver Transplantation (OLTX) Using Calcineurin-Based Immunotherapy: Risk of Development and Treatment. Transplantation, 72, 1934-1939. https://doi.org/10.1097/00007890-200112270-00012
|
[12]
|
Nagase, K., Iwasaki, K., Nozaki, K. and Noda, K. (1994) Distribution and Protein Binding of FK506, a Potent Immunosuppres-sive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes. Journal of Pharmacy and Pharmacology, 46, 113-117. https://doi.org/10.1111/j.2042-7158.1994.tb03752.x
|
[13]
|
Naesens, M., Kuypers, D. and Sarwal, M. (2009) Calcineurin Inhibitor Nephrotoxicity. Clinical Journal of the American Society of Nephrology: CJASN, 4, 481-508. https://doi.org/10.2215/CJN.04800908
|
[14]
|
Venkataramanan, R., Shaw, L.M., Sarkozi, L., et al. (2001) Clinical Utility of Monitoring Tacrolimus Blood Concentrations in liver Transplant Patients. The Journal of Clinical Pharmacol-ogy, 41, 542-551.
https://doi.org/10.1177/00912700122010429
|
[15]
|
Rovira, P., Mascarell, L. and Truffa-Bachi, P. (2000) The Impact of Immunosuppressive Drugs on the Analysis of T Cell Activation. Current Medicinal Chemistry, 7, 673-692. https://doi.org/10.2174/0929867003374778
|
[16]
|
Wieland, E., Olbricht, C.J., Süsal, C., et al. (2010) Biomarkers as a Tool for Management of Immuno-Suppression in Transplant Patients. Therapeutic Drug Monitoring, 32, 560-572. https://doi.org/10.1097/FTD.0b013e3181efb3d2
|
[17]
|
US FDA Centre for Devices and Radiological Health (2002) Class II Special Controls Guidance Document: Cyclosporine and Tacrolimus Assays, Draft Guidance for Industry and FDA. Devices DoCL. Rockville.
|
[18]
|
Sood, S. and Testro, A.G. (2014) Immune Monitoring Post Liver Transplant. World Journal of Transplantation, 4, 30-39. https://doi.org/10.5500/wjt.v4.i1.30
|
[19]
|
杨扬, 邓宜南. 肝细胞癌肝移植术后免疫抑制剂的应用[J]. 临床肝胆病杂志, 2021, 37(2): 263-266.
|
[20]
|
Rodrigo, E., López-Hoyos, M., Corral, M., et al. (2012) ImmuKnow as a Diagnostic Tool for Predicting Infection and Acute Rejection in Adult Liver Transplant Recipients: A Systematic Review and Meta-Analysis. Liver Transplantation, 18, 1245-1253. https://doi.org/10.1002/lt.23497
|
[21]
|
王学浩, 徐静. CTC/CTM在肝癌肝移植中的应用前景[J]. 医学研究生学报, 2018, 31(1): 1-4.
|
[22]
|
Ni, X., Wang, Q., Gu, J., et al. (2021) Clinical and Basic Research Progress on Treg-Induced Immune Tolerance in Liver Transplantation. Frontiers in Immunology, 12, Article ID: 535012. https://doi.org/10.3389/fimmu.2021.535012
|
[23]
|
Demetris, A., Adams, D., Bellamy, C., et al. (2000) Update of the International Banff Schema for Liver Allograft Rejection: Working Recommendations for the Histopathologic Staging and Reporting of Chronic Rejection. An International Panel. Hepatology, 31, 792-799. https://doi.org/10.1002/hep.510310337
|
[24]
|
Israeli, M., Klein, T., Brandhorst, G. and Oellerich, M. (2012) Con-fronting the Challenge: Individualized Immune Monitoring after Organ Transplantation Using the Cellular Immune Func-tion Assay. Clinica Chimica Acta, 413, 1374-1378. https://doi.org/10.1016/j.cca.2012.01.033
|
[25]
|
寇建涛, 李先亮, 朱继巧, 等. 自创免疫状态量化评分标准评估肝移植受者术后免疫状态的可行性分析[J]. 中华器官移植杂志, 2020, 41(6): 362-366.
|
[26]
|
Castellaneta, A., Thomson, A.W., Nayyar, N., de Vera, M. and Maz-ariegos, G.V. (2010) Monitoring the Operationally Tolerant Liver Allograft Recipient. Current Opinion in Organ Transplantation, 15, 28-34.
https://doi.org/10.1097/MOT.0b013e328334269a
|
[27]
|
Truong, D.Q., Bourdeaux, C., Wieërs, G., Saussoy, P., Latinne, D. and Reding, R. (2009) The Immunological Monitoring of Kidney and Liver Transplant in Adult and Pediatric Recipients. Transplant Immunology, 22, 18-27.
https://doi.org/10.1016/j.trim.2009.09.008
|
[28]
|
Xue, F., Zhang, J., Han, L., et al. (2010) Immune Cell Functional Assay in Monitoring of Adult Liver Transplantation Recipients with Infection. Transplantation, 89, 620-626. https://doi.org/10.1097/TP.0b013e3181c690fa
|